drugset / Trial / NCT00354458

PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

NCT00354458 ↗

Phase 3 Completed 1102 enrolled Merck & Co., Inc. Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in subjects with acute heart failure syndrome and renal impairment.

Timeline

Start
2006-10
Primary completion
2009-07
Completion
2009-07

Outcome

Missed primary endpoint

paper Rolofylline did not have a favorable effect with respect to the primary clinical composite end point PMID 20925544 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rolofylline Small molecule 30 mg Intravenous